Mankind Pharma

Mankind Pharma Equity

The The Equity of Mankind Pharma (MANKIND.NS) as of Oct 17, 2026 is 163.00 B INR. In the previous year, The Equity was 143.32 B INR — a change of 13.73% (higher).

Equity

163.00 BINR

YoY

13.73%

Last updated:

In 2026, Mankind Pharma's equity was 163.00 B INR, a 13.73% increase from the 143.32 B INR equity in the previous year.

The Mankind Pharma Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2019
28.23 B INR
Jan 1, 2020
34.85 B INR
Jan 1, 2021
47.22 B INR
Jan 1, 2022
61.55 B INR
Jan 1, 2023
74.35 B INR
Jan 1, 2024
93.63 B INR
Jan 1, 2025
143.32 B INR
Jan 1, 2026
163.00 B INR
The Mankind Pharma Equity history
YEAREquityYoY
163.00 BINR+13.73%
143.32 BINR+53.07%
93.63 BINR+25.93%
74.35 BINR+20.80%
61.55 BINR+30.35%
47.22 BINR+35.48%
34.85 BINR+23.46%
28.23 BINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Mankind Pharma Stock analysis

What does Mankind Pharma do? Mankind Pharma Ltd., headquartered in New Delhi, India, operates in the Health Care sector, specializing in pharmaceutical formulations. The company develops, manufactures, and markets a wide range of products across acute and chronic therapeutic areas, including anti-infectives, cardiovascular, gastrointestinal, and dermatology treatments. With 18,468 employees, it serves diverse markets through its extensive portfolio of brands such as Nurokind, Telmikind, and Manforce (Rx). Listed on 9 May 2023, the firm focuses on both prescription and consumer healthcare solutions. Mankind Pharma is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Mankind Pharma's Equity

Mankind Pharma's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Mankind Pharma's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Mankind Pharma's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Mankind Pharma's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Mankind Pharma’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Mankind Pharma stock

The Equity of Mankind Pharma is 163.00 B INR in 2026.

The Equity of Mankind Pharma changed from 143.32 B INR to 163.00 B INR, representing a 13.73% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Mankind Pharma since 2006 – with annual values, charts, and detailed analysis.

The Equity's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Mankind Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Mankind Pharma

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Mankind Pharma